ResearchMoz.us

ResearchMoz is the one stop online destination to find and buy market research reports and Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Thursday 10 July 2014

China Blood Product Industry Report, 2014-2017

Posted on 22:23 by Unknown
ResearchMoz.us include new market research report" China Blood Product Industry Report, 2014-2017" to its huge collection of research reports.

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption to domestic blood products market, the total plasma volume in China blood products industry reduced by 2.8% year on year and total lot release volume declined by 7% from a year earlier in 2013, due to stock consumption, insufficient utilization of new plasma stations and production break of some companies (e.g. Guizhou Taibang Biological Products Co., Ltd and Guangdong Wellen Biological Pharmaceutical Co., Ltd. on account of upgrading and reconstruction, Shanghai RAAS Blood Products Co., Ltd. affected by floods).




However, some niche varieties of blood products, such as scarce human coagulation factor VIII, maintained higher growth in lot release volume. In 2013, the human coagulation factor VIII produced by Shandong Taibang and CNBG Shanghai Institute of Biological Products were approved for release and came into the market, making the lot release volume of the product during the same period amount to 526,000 bottles, soaring by 44.5% on year-on-year basis.


Because of robust demand from China blood products market, the total lot release volume of imported human albumin reached 14.39 million bottles (about 10g/bottle) in 2013, a year-on-year increase of 24.1%, accounting for 53.4% (45.3% in 2012) of the total lot release volume of human albumin during the same period. Assuming absolute superiority, Behring, Baxter, Grifols and Octapharma still held the ground as the top four exporters of human albumin to China.


Despite a slight year-on-year decline in output and sales volume, major Chinese blood products companies, by and large, maintained steady revenue growth in 2013, thanks to rising prices of blood products (the highest retail prices of fibrinogen and blood coagulation factor VIII rose over 50% year on year). China Biologic Products, Hualan Bio, Tiantan Biological Products, Shanghai RAAS and Yuanda Shuyang Pharmaceutical, which hold combined 60% of the total plasma volume, generated total revenue of about RMB4.2 billion in 2013, up 13.5% year on year. Among them, Shanghai RAAS, due to production halt caused by flood, earned only RMB496 million, down 25.1% year on year.


All Latest Market Research Report @ http://www.researchmoz.us/latest-report.html


Attracted by national policy support and high market prosperity, qualified Chinese blood products companies are actively engaged in construction of new plasma stations, some of which are expected to collect plasma by the end of 2014. In June 2014, Wuhan Zhongyuan Ruide Biological Product Co., Ltd. (100% controlled by Humanwell Healthcare (Group) Co., Ltd.)’s plasmapheresis center in Chibi was approved to collect plasma; In May 2014, Hualan Bio’s plasma station in Hua County, Henan Province was approved to be set up; In April 2014, Hebei Da'an Pharmaceutical (90% stake controlled by Walvax Biotechnology Co., Ltd.) carried out on-site GMP compliance certification for its plasma station in Wei County; At the end of 2013, Guangdong Shuanglin Bio-pharmacy’s plasma stations in Xi County and Jiang County of Shanxi were completed.


In addition, as the Ministry of Health stipulates that the blood products production units with registered varieties of blood products less than 6, and the blood products production units, which undertake national planned immunization task, with registered varieties of blood products less than 5, shall not apply to set up new plasmapheresis centers. Therefore, some superior blood products companies are improving their competitiveness by acquiring small ones which have single product mix but plasma stations. In June 2013, Jiangxi Boya Bio-pharmaceutical Co., Ltd. acquired 32% stake in Zhejiang Haikang Biological Products Co., Ltd., which had two plasma stations and held 41.98% stake in Xinjiang Deyuan Bioengineering Co., Ltd., which possessed 6 plasma stations. In March 2013, Shanghai RAAS set about purchasing Zhengzhou Banghe Pharmaceutical (now known as Zhengzhou RAAS) with RMB1.8 billion, with capital settlement completed in January 2014.


For More Information Kindly Contact:
Posted in | No comments

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)